Merck gets a leg-up for Keytruda in first-line kidney cancer
Bristol-Myers Squibb, Cabometyx, Eisai, Exelixis, immuno-oncology, Inlyta, Keytruda, Lenvima, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma, Sutent, Yervoy
0 Comment